Abstract Right heart failure may be caused by several etiologic factors such as pulmonary embolism, post coronary bypass, chronic obstructive pulmonary disease (COPD) and right heart infarction. Traditionally, treatment has consisted of fluid loading (volume expansion) and the use of inotropic agents. In the present series of studies, an experimental model of acute right heart failure was developed using right heart infarct. Treatment with drugs chosen to specifically improve right heart performance was then evaluated. The drugs used in this series were aminophlline, adenosine, nitric oxide (NO) and losartan. Aminophylline transiently improved cardiac index and pulmonary vascular resistance, but simultaneously caused an increase in heart rate and a decrease in stroke volume. Although it may reduce right heart afterload, aminophylline did not improve overall cardiac function in this experimental model of right heart infarction. Adenosine affected an increase in cardiac index during the adenosine infusion and in stroke index, while pulmonary vascular resistance and mean pulmonary pressure were decreased. There was a marked decrease in systemic vascular resistance as a result of the drug. Heart rate remained unchanged by the infusion. Discontinuation of the drug resulted in a rapid reversal of the hemodynamic changes. The continuous infusion of adenosine therefore appears to cause an effective arterial vasodilation, with a consequent unloading of right heart afterload. NO treatment significantly reduced right heart afterload. A significant deterioration was observed in cardiac output as well as in left and right ventricle stroke work indices. The use of NO in this model of right heart infarct affected a decrease in both right heart afterload and left heart preload, with an overall deterioration in global hemodynamics. Losartan was shown to decrease central venous pressure and wedge pressure, while cardiac output, left ventricle stroke work and stroke volume all showed improvement. Compared to the control animals, pulmonary vascular resistance, systemic vascular resistance and systemic pressures were unaffected by the drug, as was heart rate. An inhibition of angiotensin II action may therefore be of benefit in the treatment of right heart failure symptoms during the first hours after right heart infarct.

Implantation of a left ventricular assist device (LVAD) is a potential treatment in terminal heart failure. Right ventricular (RV) failure is a severe complication in these patients and sometimes requires additional placement of a right ventricular assist device (RVAD). RVAD implantation, however, is an invasive treatment associated with both increased mortality and morbidity. The aim of this thesis was to study whether partial volume exclusion of the RV through a modified Glenn shunt or cavoaortic shunt could treat severe RV failure. The ultimate goal would be to use it as an alternative to a RVAD in RV failure during LVAD therapy. Swine were used as the model animal in all studies. In Study I, experimental RV failure was induced by ischemia, and verified by hemodynamic measurements and genetic expression. Treatment with a modified Glenn shunt reduced venous stasis and improved hemodynamics in general. In Study II, experimental RV failure was induced by the same method as in Study I. Treatment with a cavoaortic shunt in addition to LVAD therapy proved to reduce venous stasis and improved hemodynamics in general, which was feasible with preserved oxygen delivery despite cyanotic shunting. In Study III, experimental RV failure was induced by pulmonary banding, and verified by hemodynamic measurements and genetic expression. Treatment with a modified Glenn shunt reduced venous stasis but did not improve hemodynamics in general compared with a control group. In Study IV, the effects of LVAD therapy and subsequent treatment with a modified Glenn shunt on the normal RV function were studied. It demonstrated that LVAD therapy can put strain on the RV by increasing stroke work and end-diastolic volume, and that these effects can be reversed by treatment with a modified Glenn shunt during LVAD therapy. In conclusion, partial volume exclusion through a modified Glenn shunt or cavoaortic shunt is a feasible treatment of experimental RV failure. Thus, it could potentially be used as an alternative treatment to a RVAD in severe RV failure during LVAD therapy.

Right ventricular function (RV) is one of the most important predictors of prognosis in many cardiovascular disease states. Despite the significance of RV function to survival, there are no therapies that directly nor selectively improve RV function. As well, the basis for RV failure is poorly understood. This is particularly relevant for patients with pulmonary arterial hypertension (PAH), where RV failure in the setting of pressure overload is the leading cause of death. PAH will be introduced in the 2nd chapter of this thesis by comparing and refining contemporary mortality risk assessment strategies. I will then explore 1) RV neurohormonal function and, 2) RV energetics, two molecular pathways thought to be involved in the pathogenesis and progression of maladaptive RV failure. I employed small animal molecular imaging using positron emission tomography (PET) to non-invasively investigate these pathways. The PET imaging techniques employed in this thesis have the unique potential for translation to human studies, to further explore disease mechanisms.

Aims To characterize the prevalence and clinical relevance of malnutrition in patients undergoing transcatheter tricuspid valve edge-to-edge repair (TTVR). Methods and results Overall, 86 consecutive patients (mean age 78 ± 7 years) with moderate-to-severe tricuspid regurgitation (TR) at prohibitive surgical risk were analysed. Mini Nutritional Assessment (MNA), quality of life assessment, 6-min walk test distance and laboratory analyses were performed before and 1 month after TTVR. A total of 43 patients (50%) underwent concomitant transcatheter mitral valve repair. According to MNA, 81 patients (94%) were malnourished or at risk of malnutrition before TTVR. Following TTVR, MNA improved in 64 patients (74%). As compared to patients without MNA improvement, patients with increased MNA score had greater reductions in TR [regurgitation volume −17.0 (interquartile range, IQR −25.0; −7.0) mL vs. −26.4 (IQR −40.3; −14.5) mL, P < 0.001] and inferior vena cava diameter. Only patients with increased MNA score displayed a decrease in N-terminal pro-brain natriuretic peptide levels [−320 (IQR −1294; 105) pg/mL vs. +708 (IQR −342; 2708) pg/mL, P = 0.009], improvements in cholinesterase levels (0.0 ± 11.9 μmoL/L vs. +10.9 ± 16.7 μmoL/L, P < 0.001) and renal function during follow-up. Beneficial effects on quality of life scores and 6-min walk test distance following TTVR were observed exclusively in patients with improvement in MNA. During a median follow-up of 6 months, patients with worsened MNA had an increased risk of death and rehospitalization for heart failure. Conclusion Nutritional impairment is common and of prognostic importance in patients undergoing TTVR. Hepatorenal function modestly improves after successful TTVR. Further study of extracardiac implications of TR-associated right heart failure is warranted to improve care in this vulnerable patient population.

yes / We investigated the steepened dynamic action potential duration (APD) restitution of rats with pulmonary artery hypertension (PAH) and right ventricular (RV) failure and tested whether the observed APD restitution properties were responsible for negative mechanical restitution in these myocytes. PAH and RV failure were provoked in male Wistar rats by a single injection of monocrotaline (MCT) and compared with saline-injected animals (CON). Action potentials were recorded from isolated RV myocytes at stimulation frequencies between 1 and 9Hz. Action potential waveforms recorded at 1Hz were used as voltage clamp profiles (action potential clamp) at stimulation frequencies between 1 and 7Hz to evoke rate-dependent currents. Voltage clamp profiles mimicking typical CON and MCT APD restitution were applied and cell shortening simultaneously monitored. Compared with CON myocytes, MCT myocytes were hypertrophied; had less polarized diastolic membrane potentials; had action potentials that were triggered by decreased positive current density and shortened by decreased negative current density; APD was longer and APD restitution steeper. APD90 restitution was unchanged by exposure to the late Na+-channel blocker (5μM) ranolazine or the intracellular Ca2+ buffer BAPTA. Under AP clamp, stimulation frequency-dependent inward currents were smaller inMCTmyocytes and were abolished by BAPTA. In MCT myocytes, increasing stimulation frequency decreased contraction amplitude when depolarization duration was shortened, to mimic APD restitution, but not when depolarization duration was maintained. We present new evidence that the membrane potential of PAH myocytes is less stable than normal myocytes, being more easily perturbed by external currents. These observations can explain increased susceptibility to arrhythmias. We also present novel evidence that negative APD restitution is at least in part responsible for the negative mechanical restitution in PAH myocytes. Thus, our study links electrical restitution remodeling to a defining mechanical characteristic of heart failure, the reduced ability to respond to an increase in demand.

L’hypertension artérielle pulmonaire (HTAP) est une maladie caractérisée par une obstruction des artères pulmonaires de petit calibre aboutissant, à terme, à une défaillance cardiaque droite. L’évolution de cette maladie est parfois émaillée d’épisodes de dégradation de l’état fonctionnel des patients, nécessitant une admission en unité de soins intensifs pour surveillance cardioscopique et administration de médicaments inotropes et/ou vasopresseurs. Peu d’éléments permettent à ce jour de guider les praticiens dans la prise en charge de ces patients et la physiopathologie de ces épisodes est assez peu connue.Dans un premier temps, nous avons retrouvé une mortalité de 41% en réanimation et testé certains facteurs pronostiques cliniques et biologiques simples issus de la pratique quotidienne dans une cohorte propective de patients avec une prise en charge standardisée. Nous avons identifié comme facteurs pronostiques la pression artérielle systémique, la natrémie, la créatininémie, la valeur de la C-reactive Proteine. Nous avons retrouvé une influence de ces épisodes sur l’évolution à moyen terme de ces épisodes. Dans un second temps nous avons testé la valeur pronostique des indices temporels de fonctionnement du ventricule gauche, suggérée par les études en imagerie par résonnance magnétique. Nous avons utilisé pour cela la tonométrie d’aplanation, outil original et non invasif. Nous avons retrouvé que la valeur de la durée d’éjection du ventricule gauche est associée au pronostic. Dans une troisième partie nous avons mesuré les conséquences et la valeur pronostique de l’épuration extra rénale en contexte d’ insuffisance rénale menaçante chez ces patients. Dans une étude rétrospective, nous avons observé 68 séances d’épuration extra-rénale continue ou discontinue. Ces séances se sont compliquées d’hypotension artérielle dans environ 50% des cas. La très haute mortalité en réanimation et à 3 mois, respectivement de 47% et 73%, soulève la question de la place de l’assistance circulatoire et de la transplantation urgente chez ces patients. Ces données soulignent la sévérité à court terme des épisodes aigus d’aggravation chez les patients porteurs d’HTAP. De plus amples données sont nécessaires pour améliorer la prise en charge de ces patients et organiser dans le meilleur délai la mise en place de thérapeutiques exceptionnelles comme l’assistance circulatoire et la transplantation pulmonaire ou cardio-pulmonaire. / Pulmonary arterial hypertension ( PAH) is a disease characterized by an obstruction of the small pulmonary arteries leading ultimately to right heart failure. The evolution of this disease is sometimes punctuated by episodes of deterioration of the functional status of patients requiring admission to intensive care unit for monitoring and administration of inotropic drugs and / or vasopressors. Few evidence to date are available to guide physicians in the care of these patients and the pathophysiology of these episodes is still elusive.In a first part, we found a mortality of 41% in the intensive care unit (ICU) and tested some simple clinical and biological prognostic factors from the daily practice in a prospective cohort of patients with a standardized management. We have identified systemic blood pressure, serum sodium, serum creatinine, serum C -reactive Protein as prognostic factors. We found an influence of these events on the medium-term evolution of the patients.In a second step we tested the prognostic value of time derived indices of left ventricular function, variables suggested by magnetic resonance imaging studies. In this purpose, we used aplanation tonometry, an original and non-invasive tool. We found that the value of the left ventricular ejection time was associated with in ICU prognosis.In the third part we measured the impact and prognostic value of renal replacement therapy in case of threatening kidney failure in these patients. In a retrospective study, we observed 68 sessions of renal replacement therapy, continuous hemofiltration and intermittent hemodialysis. These sessions were complicated by hypotension in 50 % of cases. The high in ICU mortality and three months mortilty, respectively 47% and 73%, raises the question of the role of extracorporeal life support and urgent transplantation in these patients.These data underscore the severity of acute worsening in patients with PAH. More data are needed to improve the management of these patients and determine the best timing of exceptional treatment such as circulatory support and pulmonary or cardiopulmonary transplantation.

A hipertensão arterial pulmonar (HAP) é caracterizada pelo aumento da resistência vascular pulmonar (RVP). Em decorrência, há elevação da pós-carga imposta ao ventrículo direito (VD) e hipertrofia. Assim, com aumento de consumo de O2 pelo miocárdio, é provável que o estresse oxidativo esteja participando do desenvolvimento e progressão desta doença. Sabe-se que o bloqueio beta-adrenérgico diminui a mortalidade de pacientes com insuficiência cardíaca à esquerda, porém pouquíssimas pesquisas referem sua utilização na insuficiência cardíaca à direita. O bucindolol é um beta-bloqueador que atua nos receptores β1, β2, α1 e com propriedade simpatolítica. O objetivo deste estudo foi testar a hipótese de que o tratamento com bucindolol poderia reduzir a hipertrofia do VD e melhorar a função sistólica e diastólica do miocárdio. Foram utilizados ratos Wistar machos pesando 130±10 gramas divididos em quatro grupos (n=7-10/grupo): monocrotalina sem bucindolol (MCT SEM BCD), monocrotalina bucindolol (MCT+BCD), controle sem bucindolol (CTR SEM BCD) e controle bucindolol (CTR+BCD). A HAP foi induzida por meio de uma dose única de monocrotalina (60 mg/Kg – i.p.). Após duas semanas, os animas foram tratados por sete dias com bucindolol (2 mg/Kg/dia – i.p.) ou veículo. No 22º dia após a administração da monocrotalina, os animais foram anestesiados (i.p.) com quetamina (90 mg/Kg) e xilazina (10 mg/Kg), submetidos à ecocardiografia, cateterismo da artéria femoral, cateterismo do VD e decapitados, com posterior coleta dos tecidos. Os resultados foram avaliados utilizando ANOVA de duas vias (Sigma Plot 12.0) seguida pelo 8 teste de Student-Newman-Keuls, com nível de significância P<0,05. Os resultados serão apresentados na versão completa desta dissertação. / Pulmonary arterial hypertension is a rapidly progressive disease with poor prognosis, characterized by increase in pulmonary vascular resistance. As a result, there is an elevation of afterload imposed to the right ventricle and hypertrophy. Thus, since there is a rise in myocardial oxygen consumption, it is probable that oxidative stress is contributing to the development and progression of this disease. It is known that beta-adrenergic blockade reduces mortality in patients with left ventricular heart failure, but limited studies relate their use in right ventricular heart failure. The bucindolol is a beta-blocker that acts on receptors β1, β2, α1 and presents sympatholytic property. The aim of this study was to test the hypothesis that treatment with bucindolol could reduce right ventricular hypertrophy and improve systolic and diastolic function of the myocardium. Male Wistar rats weighing 130±10 grams were divided into four groups (n=7-10/group): monocrotaline without bucindolol (MCT WITHOUT BCD), monocrotaline bucindolol (MCT+BCD), control without bucindolol (CTR WITHOUT BCD) and control bucindolol (CTR+BCD). Pulmonary arterial hypertension was induced by a single dose of monocrotaline (60 mg/Kg – i.p.). After two weeks, the animals were treated for seven days with bucindolol (2 mg/Kg/day – i.p.) or vehicle. Twenty-two days after administration of monocrotaline, the animals were anesthetized intraperitoneally with ketamine (90 mg/Kg) and xylazine (10 mg/Kg), underwent echocardiography, catheterization of the femoral artery and of the right ventricle, decapitation and subsequent collection of tissues (heart, lungs, liver and tibia). The results were analyzed using two-way ANOVA (Sigma Plot 12.0) followed by 10 Student-Newman-Keuls test, with P<0.05 of significance level. Results will be presented in the full version.

A hipertensão arterial pulmonar (HAP) é caracterizada pelo aumento da resistência vascular pulmonar (RVP). Em decorrência, há elevação da pós-carga imposta ao ventrículo direito (VD) e hipertrofia. Assim, com aumento de consumo de O2 pelo miocárdio, é provável que o estresse oxidativo esteja participando do desenvolvimento e progressão desta doença. Sabe-se que o bloqueio beta-adrenérgico diminui a mortalidade de pacientes com insuficiência cardíaca à esquerda, porém pouquíssimas pesquisas referem sua utilização na insuficiência cardíaca à direita. O bucindolol é um beta-bloqueador que atua nos receptores β1, β2, α1 e com propriedade simpatolítica. O objetivo deste estudo foi testar a hipótese de que o tratamento com bucindolol poderia reduzir a hipertrofia do VD e melhorar a função sistólica e diastólica do miocárdio. Foram utilizados ratos Wistar machos pesando 130±10 gramas divididos em quatro grupos (n=7-10/grupo): monocrotalina sem bucindolol (MCT SEM BCD), monocrotalina bucindolol (MCT+BCD), controle sem bucindolol (CTR SEM BCD) e controle bucindolol (CTR+BCD). A HAP foi induzida por meio de uma dose única de monocrotalina (60 mg/Kg – i.p.). Após duas semanas, os animas foram tratados por sete dias com bucindolol (2 mg/Kg/dia – i.p.) ou veículo. No 22º dia após a administração da monocrotalina, os animais foram anestesiados (i.p.) com quetamina (90 mg/Kg) e xilazina (10 mg/Kg), submetidos à ecocardiografia, cateterismo da artéria femoral, cateterismo do VD e decapitados, com posterior coleta dos tecidos. Os resultados foram avaliados utilizando ANOVA de duas vias (Sigma Plot 12.0) seguida pelo 8 teste de Student-Newman-Keuls, com nível de significância P<0,05. Os resultados serão apresentados na versão completa desta dissertação. / Pulmonary arterial hypertension is a rapidly progressive disease with poor prognosis, characterized by increase in pulmonary vascular resistance. As a result, there is an elevation of afterload imposed to the right ventricle and hypertrophy. Thus, since there is a rise in myocardial oxygen consumption, it is probable that oxidative stress is contributing to the development and progression of this disease. It is known that beta-adrenergic blockade reduces mortality in patients with left ventricular heart failure, but limited studies relate their use in right ventricular heart failure. The bucindolol is a beta-blocker that acts on receptors β1, β2, α1 and presents sympatholytic property. The aim of this study was to test the hypothesis that treatment with bucindolol could reduce right ventricular hypertrophy and improve systolic and diastolic function of the myocardium. Male Wistar rats weighing 130±10 grams were divided into four groups (n=7-10/group): monocrotaline without bucindolol (MCT WITHOUT BCD), monocrotaline bucindolol (MCT+BCD), control without bucindolol (CTR WITHOUT BCD) and control bucindolol (CTR+BCD). Pulmonary arterial hypertension was induced by a single dose of monocrotaline (60 mg/Kg – i.p.). After two weeks, the animals were treated for seven days with bucindolol (2 mg/Kg/day – i.p.) or vehicle. Twenty-two days after administration of monocrotaline, the animals were anesthetized intraperitoneally with ketamine (90 mg/Kg) and xylazine (10 mg/Kg), underwent echocardiography, catheterization of the femoral artery and of the right ventricle, decapitation and subsequent collection of tissues (heart, lungs, liver and tibia). The results were analyzed using two-way ANOVA (Sigma Plot 12.0) followed by 10 Student-Newman-Keuls test, with P<0.05 of significance level. Results will be presented in the full version.

A hipertensão arterial pulmonar (HAP) é caracterizada pelo aumento da resistência vascular pulmonar (RVP). Em decorrência, há elevação da pós-carga imposta ao ventrículo direito (VD) e hipertrofia. Assim, com aumento de consumo de O2 pelo miocárdio, é provável que o estresse oxidativo esteja participando do desenvolvimento e progressão desta doença. Sabe-se que o bloqueio beta-adrenérgico diminui a mortalidade de pacientes com insuficiência cardíaca à esquerda, porém pouquíssimas pesquisas referem sua utilização na insuficiência cardíaca à direita. O bucindolol é um beta-bloqueador que atua nos receptores β1, β2, α1 e com propriedade simpatolítica. O objetivo deste estudo foi testar a hipótese de que o tratamento com bucindolol poderia reduzir a hipertrofia do VD e melhorar a função sistólica e diastólica do miocárdio. Foram utilizados ratos Wistar machos pesando 130±10 gramas divididos em quatro grupos (n=7-10/grupo): monocrotalina sem bucindolol (MCT SEM BCD), monocrotalina bucindolol (MCT+BCD), controle sem bucindolol (CTR SEM BCD) e controle bucindolol (CTR+BCD). A HAP foi induzida por meio de uma dose única de monocrotalina (60 mg/Kg – i.p.). Após duas semanas, os animas foram tratados por sete dias com bucindolol (2 mg/Kg/dia – i.p.) ou veículo. No 22º dia após a administração da monocrotalina, os animais foram anestesiados (i.p.) com quetamina (90 mg/Kg) e xilazina (10 mg/Kg), submetidos à ecocardiografia, cateterismo da artéria femoral, cateterismo do VD e decapitados, com posterior coleta dos tecidos. Os resultados foram avaliados utilizando ANOVA de duas vias (Sigma Plot 12.0) seguida pelo 8 teste de Student-Newman-Keuls, com nível de significância P<0,05. Os resultados serão apresentados na versão completa desta dissertação. / Pulmonary arterial hypertension is a rapidly progressive disease with poor prognosis, characterized by increase in pulmonary vascular resistance. As a result, there is an elevation of afterload imposed to the right ventricle and hypertrophy. Thus, since there is a rise in myocardial oxygen consumption, it is probable that oxidative stress is contributing to the development and progression of this disease. It is known that beta-adrenergic blockade reduces mortality in patients with left ventricular heart failure, but limited studies relate their use in right ventricular heart failure. The bucindolol is a beta-blocker that acts on receptors β1, β2, α1 and presents sympatholytic property. The aim of this study was to test the hypothesis that treatment with bucindolol could reduce right ventricular hypertrophy and improve systolic and diastolic function of the myocardium. Male Wistar rats weighing 130±10 grams were divided into four groups (n=7-10/group): monocrotaline without bucindolol (MCT WITHOUT BCD), monocrotaline bucindolol (MCT+BCD), control without bucindolol (CTR WITHOUT BCD) and control bucindolol (CTR+BCD). Pulmonary arterial hypertension was induced by a single dose of monocrotaline (60 mg/Kg – i.p.). After two weeks, the animals were treated for seven days with bucindolol (2 mg/Kg/day – i.p.) or vehicle. Twenty-two days after administration of monocrotaline, the animals were anesthetized intraperitoneally with ketamine (90 mg/Kg) and xylazine (10 mg/Kg), underwent echocardiography, catheterization of the femoral artery and of the right ventricle, decapitation and subsequent collection of tissues (heart, lungs, liver and tibia). The results were analyzed using two-way ANOVA (Sigma Plot 12.0) followed by 10 Student-Newman-Keuls test, with P<0.05 of significance level. Results will be presented in the full version.

La survenue d’une défaillance ventriculaire droite est associée à une augmentation de mortalité dans de nombreuses situations cliniques, particulièrement chez les patients atteints d’hypertension pulmonaire chronique. Les mécanismes conduisant à la dysfonction et la défaillance du ventricule droit lorsqu’il est soumis à une surcharge chronique de pression sont complexes et demeurent mal connus. Si une bonne adéquation entre les apports et les besoins accrus en oxygène est essentielle pour le maintien d’une fonction ventriculaire droite adaptée, il semblerait que l’altération de la microvascularisation myocardique pourrait être responsable de la présence d’ischémie myocardique et pourrait contribuer à la transition de la phase adaptée à la phase non adaptée de l’hypertrophie ventriculaire droite. La mitochondrie étant l’organelle oxygéno-dépendante responsable de la production d’énergie, l’intégrité de ses capacités oxydatives est également essentielle au bon fonctionnement du ventricule droit. Il semblerait que le métabolisme mitochondrial soit altéré dans le ventricule droit défaillant mais il existe peu de données au stade précoce dysfonction ventriculaire droite. Afin de mieux comprendre l’importance de ces mécanismes, nous avons modélisé l’hypertension artérielle pulmonaire chez le porc.La première partie de ce travail a consisté à mettre en évidence l’association entre l’altération de la microvascularisation et l’adaptation ventriculaire droite à une surcharge de pression. Pour cela, nous avons modélisé l’hypertension pulmonaire chez deux modèles porcins différents. L’un était un modèle de shunt entre la crosse aortique et le tronc de l’artère pulmonaire (SHUNT), l’autre était un modèle d’hypertension artérielle pulmonaire post-embolique (CTEPH). Un remodelage structurel et fonctionnel du ventricule droit était observé dans les 2 modèles. Dans cette étude, nous avons mis en évidence que la dysfonction ventriculaire droite précoce était associée à (1) un mismatch entre la microvascularisation et l’hypertrophie ventriculaire droite, traduit par une baisse de la densité capillaire, (2) à une baisse du ratio entre la densité capillaire et la charge de travail du ventricule droit (Strokework) et (3) à une augmentation de la fibrose myocardique.Dans la deuxième partie de cette thèse, nous avons étudié et comparé la densité capillaire et la fibrose myocardique ventriculaire droite chez 14 patients atteints de syndrome d’Eisenmenger et 14 patients atteints d’hypertension artérielle pulmonaire chronique. Ces 28 patients présentaient une défaillance ventriculaire droite symptomatique et avaient été traité par une transplantation cœur-poumon. La densité capillaire ventriculaire droite était identique dans les deux groupes et était environ 1,5 fois plus basse que dans un ventricule droit normal, confirmant l’atteinte microvasculaire chez ces patients.La troisième partie de ce travail a consisté à étudier les capacités respiratoires mitochondriales au cours du remodelage ventriculaire droit lorsqu’il est soumis à une surcharge chronique de pression. Il a ainsi été montré que, dans notre modèle porcin d’hypertension artérielle pulmonaire postembolique, les capacités respiratoires mitochondriales mesurées selon la méthode des fibres myocardiques perméabilisées étaient globalement diminuées, précocement dans l’évolution et sans diminution de la masse mitochondriale en microscopie électronique. Nous n’avons pas mis en évidence de modification de d’utilisation préférentiel de substrat par la mitochondrie au cours du temps dans cette étude.De manière générale, ces résultats démontrent le rôle de l’atteinte microvasculaire et de la dysfonction mitochondriale dans la dysfonction ventriculaire droite. Les voies moléculaires communes à ces deux mécanismes (PGC-1, HiF-1 entre autres) font l’objet d’étude afin d’identifier de nouvelles cibles thérapeutiques. / Right ventricular failure is associated with an increased mortality in several clinical features, especially in patients with pulmonary hypertension. Underlying mechanisms of right ventricular dysfunction and failure in chronic pressure overload are complex and still subject to debate. The balance between the supply and the increased need in oxygen is crucial to maintain an adapted right ventricular function. However, an impairment of the myocardial microvascularisation could lead to myocardial ischemia and could participate to the transition between adapted and non-adapted right ventricular hypertrophy. As mitochondrion are involved in the entire oxygen-dependent energy production in cardiomyocytes, their integrity is also essential for a good right ventricular function. It is suggested that mitochondrial metabolism is impaired in right ventricular failure. However, only few data exist at the early stage of right ventricular dysfunction. To better understand the importance of such mechanisms, we used a model of chronic pulmonary hypertension in piglets.The first aim of this thesis was to study the association between microvascularisation impairment and right ventricular adaptation to chronic pressure overload. We compared two different piglet models of pulmonary hypertension. The first model was a systemic-to-pulmonary shunt (SHUNT) between the aortic arch and the pulmonary trunk. The second model reproduced thromboembolic pulmonary hypertension (CTEPH). In this work, we showed that early right ventricular dysfunction was associated with (1) a mismatch between microvascularisation and right ventricular hypertrophy as showed by a decreased capillary density, (2) an importance of the capillary density to right ventricular stroke work ratio and (3) an increased of myocardial fibrosis.In the second part of this thesis, we studied and compared the capillary density and myocardial fibrosis in right ventricles of 14 Eisenmenger Syndrome patients and 14 patients with chronic pulmonary arterial hypertension. All 28 patients had symptomatic right ventricular failure and underwent heart-lung transplantation in our institution. Capillary density was not different between the two groups and was almost 1.5-fold lower than in normal right ventricle, confirming the impairment of microvascularisation in these patients.In the third part of this work, we studied the mitochondrial respiratory capacities in the setting of right ventricular remodeling under chronic pressure overload. Thus, we showed that, in our swine CTEPH model, the mitochondrial respiratory capacities were globally and early impaired. The mitochondrial mass assessed in transmission electronic microscopy was not decreased. We didn’t observe any modification of substrate use over time.Taking together, these results showed that microvascular impairment and mitochondrial dysfunction had an important role in the early right ventricular dysfunction. Molecular pathways involved in both mechanisms are currently studied to find new targeted therapeutics.